S276
Clinical - Breast
ESTRO 2026
Sk ł odowska-Curie Bialystok Oncology Center, Bia ł ystok, Poland. 6 Department of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie National Research Institute of Oncology-National Research Institute, Warszawa, Poland. 7 Department of Oncology and Radiotherapy, Faculty of Medicine in Hradec Kralove and University Hospital in Hradec Kralove, Charles University, Hradec Králové, Czech Republic. 8 Department of Oncology, Third Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, Prague, Czech Republic. 9 Department of Metabolic Diseases and Immuno- oncology, Medical University of Lublin, Lublin, Poland. 10 Department of Clinical Oncology, Holy Cross Cancer Center, Kielce, Poland. 11 Department of Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic. 12 II. Oncology Clinic of LFUK, National Cancer Institute, Bratislava, Slovakia. 13 Department of Proliferative Diseases, Nicolaus Copernicus Multidisciplinary Centre for Oncology and Traumatology, Ł ód ź , Poland. 14 Department of Oncology, First Faculty of Medicine, Charles University in Prague, and Bulovka University Hospital, Prague, Czech Republic. 15 Department of Oncology and Radiotherapy, Faculty of Medicine in Pilsen, Charles University; University Hospital Pilsen, Plzen, Czech Republic. 16 Oddzia ł Onkologii i Radioterapii, Szpitale Pomorskie sp. z o.o., Gdynia, Poland. 17 Department of Oncology, Stefan Kukura Hospital Michalovce, Michalovce, Slovakia. 18 Department of Oncology, Wroc ł aw Medical University, Wroc ł aw, Poland. 19 Department of Gynecological Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow Branch, Kraków, Poland. 20 Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Kraków, Poland Purpose/Objective: Antibody–drug conjugates (ADCs) have substantially expanded treatment options in breast cancer. Sacituzumab govitecan (SG) significantly prolongs survival in metastatic triple-negative breast cancer (mTNBC). As systemic therapies like SG extend patient survival, more mTNBC patients could become candidates for local treatments such as stereotactic body radiotherapy (SBRT). However, SBRT remains underutilized in mTNBC compared to HER2-positive or hormone receptor-positive/HER2-negative disease, reflecting its historically aggressive course and shorter prognosis. The safety and efficacy of combining SG with radiotherapy (RT) remain unclear, with potential added toxicities a concern. We analyzed a multinational cohort to assess whether adding radiotherapy, particularly SBRT, improves outcomes. Material/Methods: This retrospective study included 306 patients with
therapy. Half of the cohort (50%, n=31) reported sexual dissatisfaction. Psychological symptoms were noted in 75.8% (n=47), including reduced sexual desire (66.1%), depressive symptoms (59.7%), and sleep disorders (56.5%). Vaginal symptoms were reported by 71% (n=44), primarily dryness (43.5%) and decreased sensitivity (38.7%). Relational difficulties were common (71%). The vast majority of patients (85.5%) attributed their sexual deterioration to anticancer treatments, specifically chemotherapy (66.1%) and surgery (46.8%). Univariate analysis revealed that only chemotherapy was significantly associated with decreased sexual satisfaction (p=0.043).Hormone therapy showed a strong trend toward association with vaginal symptoms (p = 0.056).). Despite 83.9% of women acknowledging the importance of sexual health, only 6.5% had discussed it with their healthcare providers. Conclusion: This study showed a high prevalent and multidimensional sexual dysfunction in young BC survivors. Chemotherapy was the only treatment significantly related to decreased sexual satisfaction.The profound disconnect between the high perceived importance of sexual health and the minimal clinical communication underscores the need to systematically integrate assessment and management of sexual disorders into oncologic follow- up care. Keywords: breast cancer, sexual health, cancer treatments SBRT in Combination with Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer: A Multinational Cohort Study Anna Polakiewicz-Gilowska 1 , Ma ł gorzata Pieni ąż ek 2 , Milos Holanek 3 , Zuzana Biel č iková 4 , Karolina Winsko- Szcz ę snowicz 5 , Aleksandra Konieczna 6 , Iveta Kolarova 7 , Renata Soumarova 8 , Tomasz Ciszewski 9 , Justyna Ż ubrowska 10 , Hana Studentova 11 , Miroslava Malejcikova 12 , Agnieszka M ł odzi ń ska 6 , Maja Lisisk- Habib 13 , Anika P ę kala 13 , Daniel Krejci 14 , Jan Sustr 15 , Iwona Danielewicz 16 , Lenka Rusinova 17 , Bogumi ł a Czartoryska -Ar ł ukowicz 5 , Aleksandra Ł acko 18 , Renata Pacholczak-Madej 19 , Micha ł Jarz ą b 1 , Miros ł awa Püsküllüo ğ lu 20 , Marcin Kubeczko 1 1 Breast Cancer Center, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland. 2 1Department of Oncology, Wroc ł aw Medical University, Wroc ł aw, Poland. 3 Faculty of Medicine, Masaryk University, and Masaryk Memorial Cancer Institute, Brno, Czech Republic. 4 Department of Oncology, First Faculty of Medicine, Charles University, and General University Hospital, Prague, Czech Republic. 5 Department of Clinical Oncology, M. Digital Poster Highlight 2416
Made with FlippingBook - Share PDF online